NI201900110A - Métodos y composiciones para el tratamiento de apnea del sueño - Google Patents
Métodos y composiciones para el tratamiento de apnea del sueñoInfo
- Publication number
- NI201900110A NI201900110A NI201900110A NI201900110A NI201900110A NI 201900110 A NI201900110 A NI 201900110A NI 201900110 A NI201900110 A NI 201900110A NI 201900110 A NI201900110 A NI 201900110A NI 201900110 A NI201900110 A NI 201900110A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compositions
- treatment
- methods
- sleep apnea
- nri
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US201762558814P | 2017-09-14 | 2017-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900110A true NI201900110A (es) | 2020-03-18 |
Family
ID=63918622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900110A NI201900110A (es) | 2017-04-28 | 2019-10-25 | Métodos y composiciones para el tratamiento de apnea del sueño |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11123313B2 (enExample) |
| EP (1) | EP3615016A4 (enExample) |
| JP (3) | JP7373997B2 (enExample) |
| KR (3) | KR102682159B1 (enExample) |
| CN (2) | CN110799181A (enExample) |
| AU (3) | AU2018260666B2 (enExample) |
| BR (1) | BR112019022483A2 (enExample) |
| CA (1) | CA3061468A1 (enExample) |
| CO (1) | CO2019013180A2 (enExample) |
| CR (1) | CR20190546A (enExample) |
| DO (1) | DOP2019000274A (enExample) |
| EC (1) | ECSP19084058A (enExample) |
| GE (4) | GEP20227387B (enExample) |
| MA (1) | MA49069A (enExample) |
| MX (2) | MX394941B (enExample) |
| MY (1) | MY200172A (enExample) |
| NI (1) | NI201900110A (enExample) |
| PH (1) | PH12019502427A1 (enExample) |
| SG (2) | SG10202111623TA (enExample) |
| UA (1) | UA127759C2 (enExample) |
| WO (1) | WO2018200775A1 (enExample) |
| ZA (1) | ZA201907158B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799181A (zh) * | 2017-04-28 | 2020-02-14 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| PT3746126T (pt) * | 2018-01-30 | 2024-10-21 | Apnimed Inc Delaware | Métodos e composições para o tratamento de apneia do sono ou roncopatia simples |
| CN108309261B (zh) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | 一种猝死预警方法及装置和系统 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| JP2022506113A (ja) * | 2018-10-31 | 2022-01-17 | アプニメッド，インコーポレイテッド（デラウェア） | 睡眠時無呼吸を治療するための方法及び組成物 |
| PH12021551850A1 (en) * | 2019-02-08 | 2022-05-11 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| WO2021091902A1 (en) * | 2019-11-04 | 2021-05-14 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| JP7776442B2 (ja) | 2020-05-05 | 2025-11-26 | アプニメッド，インコーポレイテッド（デラウェア） | （ｒ）－オキシブチニン塩酸塩の多形形態 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| RU2757470C1 (ru) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы |
| WO2022155162A1 (en) * | 2021-01-14 | 2022-07-21 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| JP2024508498A (ja) * | 2021-03-04 | 2024-02-27 | アプニメッド，インコーポレイテッド（デラウェア） | 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ |
| EP4322930A1 (en) * | 2021-04-16 | 2024-02-21 | Apnimed, Inc. (Delaware) | Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea |
| EP4355333A1 (en) * | 2021-06-17 | 2024-04-24 | Apnimed, Inc. (Delaware) | Norepinephrine reuptake inhibitors for treating sleep apnea |
| US20240358709A1 (en) * | 2021-08-31 | 2024-10-31 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| EP4452242A1 (en) | 2021-12-22 | 2024-10-30 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| CN118434414A (zh) | 2021-12-22 | 2024-08-02 | 拜耳公司 | 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与毒蕈碱受体拮抗剂的结合物 |
| KR20240127384A (ko) * | 2021-12-22 | 2024-08-22 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 task1/3 채널 차단제와 노르에피네프린 재흡수 억제제의 조합물 |
| WO2023219991A1 (en) * | 2022-05-13 | 2023-11-16 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
| CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| WO2006023702A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
| CA2590802A1 (en) * | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| CN103458899A (zh) * | 2011-01-28 | 2013-12-18 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| CN110799181A (zh) * | 2017-04-28 | 2020-02-14 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| PT3746126T (pt) * | 2018-01-30 | 2024-10-21 | Apnimed Inc Delaware | Métodos e composições para o tratamento de apneia do sono ou roncopatia simples |
-
2018
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/zh active Pending
- 2018-04-26 MX MX2019012729A patent/MX394941B/es unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en not_active Ceased
- 2018-04-26 KR KR1020197034523A patent/KR102682159B1/ko active Active
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 CN CN202411366994.9A patent/CN119185558A/zh active Pending
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/ko not_active Ceased
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
- 2018-04-26 CR CR20190546A patent/CR20190546A/es unknown
- 2018-04-26 GE GEAP202416602A patent/GEAP202416602A/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 UA UAA201910615A patent/UA127759C2/uk unknown
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 MA MA049069A patent/MA49069A/fr unknown
- 2018-04-26 BR BR112019022483-1A patent/BR112019022483A2/pt unknown
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 GE GEAP201816320A patent/GEP20257788B/en unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/ja active Active
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 KR KR1020257032249A patent/KR20250145704A/ko active Pending
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/es unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/es unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/es unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/es unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/es unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/ja active Pending
- 2023-07-19 US US18/355,178 patent/US20240189261A1/en not_active Abandoned
-
2024
- 2024-03-04 US US18/594,885 patent/US20240261239A1/en not_active Abandoned
-
2025
- 2025-07-31 JP JP2025128090A patent/JP2025169279A/ja active Pending
- 2025-09-11 AU AU2025230729A patent/AU2025230729A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013180A2 (es) | Métodos y composiciones para el tratamiento de apnea del sueño | |
| MX2025004365A (es) | Metodos y composiciones para el tratamiento de la apnea del sue?o | |
| MX2024001713A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| CO2018005905A2 (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
| DOP2019000171A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| DOP2019000172A (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| CL2023002824A1 (es) | Métodos y composiciones para tratar la apnea del sueño | |
| EA201992569A1 (ru) | Способы и композиции для лечения апноэ во сне | |
| NZ758564B2 (en) | Methods and compositions for treating sleep apnea | |
| AR110417A1 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| MX2024007767A (es) | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. | |
| CO7160013A1 (es) | Cinturón para detectar, corregir, prevenir y monitorear la apnea del sueño | |
| BR112014029577A2 (pt) | uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono | |
| CL2021001315A1 (es) | Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño | |
| Hui-min | Effect of dezocine analgesia on the incidence of the postoperative delirium in orthopedic patients | |
| CO7240357A2 (es) | Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal |